CAR T-cell therapy has emerged as a promising treatment for multiple myeloma (MM), offering a novel approach that complements traditional therapies such as autologous stem cell transplants and immunomodulatory drugs. This therapy involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs) that target specific antigens on myeloma cells, enabling them to recognize and destroy cancer cells. Despite challenges such as cytokine release syndrome (CRS) and neurotoxicity, recent approvals of CAR T-cell therapies, including those targeting BCMA (B-cell maturation antigen), have shown significant efficacy in treating relapsed/refractory MM (RRMM). Several CAR T-cell therapies targeting BCMA, such as bb2121, bb21217, LCAR-B38M, P-BCMA-101, MCARH171, BRD015, and Descartes-08, have demonstrated promising results in clinical trials, with high response rates and durable responses. These therapies have shown effectiveness across various BCMA expression levels, with some achieving complete responses and minimal residual disease (MRD) negativity. Additionally, other CAR T-cell therapies targeting antigens such as CD19, CD38, CD138, SLAMF7, and CD70 have also shown potential in treating MM, although they face challenges such as neurotoxicity and off-target effects. The development of CAR T-cell therapies continues to evolve, with ongoing research focusing on improving their safety, efficacy, and durability. Strategies such as incorporating safety switches, optimizing CAR design, and exploring combination therapies are being investigated to enhance the therapeutic potential of CAR T-cell therapy in MM. These advancements highlight the promising future of CAR T-cell therapy in the treatment of multiple myeloma.CAR T-cell therapy has emerged as a promising treatment for multiple myeloma (MM), offering a novel approach that complements traditional therapies such as autologous stem cell transplants and immunomodulatory drugs. This therapy involves genetically modifying a patient's T cells to express chimeric antigen receptors (CARs) that target specific antigens on myeloma cells, enabling them to recognize and destroy cancer cells. Despite challenges such as cytokine release syndrome (CRS) and neurotoxicity, recent approvals of CAR T-cell therapies, including those targeting BCMA (B-cell maturation antigen), have shown significant efficacy in treating relapsed/refractory MM (RRMM). Several CAR T-cell therapies targeting BCMA, such as bb2121, bb21217, LCAR-B38M, P-BCMA-101, MCARH171, BRD015, and Descartes-08, have demonstrated promising results in clinical trials, with high response rates and durable responses. These therapies have shown effectiveness across various BCMA expression levels, with some achieving complete responses and minimal residual disease (MRD) negativity. Additionally, other CAR T-cell therapies targeting antigens such as CD19, CD38, CD138, SLAMF7, and CD70 have also shown potential in treating MM, although they face challenges such as neurotoxicity and off-target effects. The development of CAR T-cell therapies continues to evolve, with ongoing research focusing on improving their safety, efficacy, and durability. Strategies such as incorporating safety switches, optimizing CAR design, and exploring combination therapies are being investigated to enhance the therapeutic potential of CAR T-cell therapy in MM. These advancements highlight the promising future of CAR T-cell therapy in the treatment of multiple myeloma.